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↑ What is "already known" in this topic: {#what1}
========================================

Based on a report from Iran, the first cause of mortality from the view of the number of fatalities has belonged to CVD. Despite its high costs, there are evidence proving the effect of eplerenone in treating CVDs.

→What this article adds: {#what2}
========================

Compared to current treatments for CVD in Iran, our systematic review showed that eplerenone has a far greater impact on reducing the duration of hospitalization, decreasing the mortality rate of the cardiovascular patients, and ensuring the treatment efficacy and safety.

Introduction {#s1}
============

Cardiovascular diseases (CVDs) are the main cause of mortality in most high- income counties (HICs) as well as in low- and middle- income countries (LMICs). Moreover, despite the new advanced treatments and the use of sophisticated techniques and surgical interventions, mortality rate due to CVD is very high ([@R1]). According to the WHO's report, mortality and disability from CVD and cerebrovascular accident, or stroke involve more than 12 million individuals worldwide annually. WHO also predicts that if the current trends continue, 25% of healthy life years will be lost by 2020 worldwide, with a large share belonging to the LMICs ([@R2]). In Iran, CVD is considered as the most common cause of mortality ([@R3]).

Aside from deaths due to unprecedented events such as Bam earthquake, the annual number of deaths in Iran has been around 320,203 in 2003. Meanwhile, the first cause of mortality from the view of the number of fatalities was belonged to CVD (72,682 males and 62,068 for females) followed by unintentional accidents as the second cause of mortality in Iran ([@R4]).

Therefore, due to lack of resources, especially in the health sector and increased health care expenditures, developing solutions and implementing cost-effective interventions are of prime importance due to the high rate of mortality due to CVD and the high costs of health care services for these disorders ([@R5],[@R6]).

A large part of national health budget and resource planning has already been allocated to non-communicable diseases, and diagnosis and treatment of cardiovascular disorders. Core expenditure relates to medications and drugs. Annually, many medications log in the health care system for the treatment of CVD. Eplerenone is one of the medications which is in the light spot and is medicated by cardiovascular specialists for patients in the recent years ([@R7]-[@R10]). Many studies have been conducted on the safety and efficacy of eplerenone ([@R11]-[@R14]). In the recent years, some studies have been designed and conducted to measure the cost-effectiveness of eplerenone in treating CVD ([@R15]-[@R18]). Although this medicine is produced in HICs extensively is entered from LMICs into the healthcare system.

Due to the high cost of such medications, high expenditures will be imposed on the healthcare system and the community. Thus, the present study aimed at systematically reviewing studies on the cost-effectiveness of eplerenone in treating cardiovascular diseases.

Methods {#s2}
=======

The adopted approach for systematic review was from \"Systematic Review to Support Evidence-Based Medicine\" book ([@R19]). The data were collected using keywords such as eplerenone, aldosterone antagonists, Inspra, cost-effectiveness, economic, chronic heart failure, heart, and cardiac from the following databases: Google Scholar, PubMed, Scopus, Cochrane, Science Direct, Health Technology Assessment database, MagIran, SID, IranMedex, and hand-searching of journals and selecting articles from resources. In the last step of the literature search, gray literature was also searched and we did contact the experts. The articles conducted during 1990 and 2016 were selected for the review. The process of selecting eligible articles is shown in [Diagram. 1](#D1){ref-type="fig"}
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Inclusion criteria were articles in the field of cardiovascular diseases, studies that compared the cost-effectiveness of eplerenone with other medications, and articles that reported at least 1 of the mentioned factors below: gained life years, total costs, and expenditures and cost-effectiveness ratios of treating cardiovascular patients with eplerenone per QALY. All types of observational and interventional studies, except case studies, and published articles in Persian and English which were consistent with the above- mentioned considerations were reviewed in this study. Exclusion criteria were as follow: papers presented at conferences, case reports, and articles that did not have the necessary qualifications.

Quality Assessment of the Selected Articles {#s2-0-1}
-------------------------------------------

According to the Drummond\'s checklist for assessing the quality of economic evaluations and the agreement between the 2 researchers of this study, quality of the articles was assessed in accordance with the existing standards, and articles that did not meet the necessary qualifications were excluded.

Data Analysis {#s2-0-2}
-------------

Selected articles were thoroughly studied and the required data were extracted and summarized using the designed tables. The Endnote X5 (resource management software) was used to organize, read the titles and abstracts, and identify duplicates.

Results {#s5}
=======

From 296 articles extracted from the references, 9 were related to the objectives of the study and thus included for review. ​​

In general, the cost-effectiveness of eplerenone was investigated in 31 757 patients with cardiovascular diseases. In the 6 reviewed studies, cost-effectiveness of eplerenone was investigated in patients with heart failure after myocardial infarction. In 3 studies, the comparison group included the standard treatment; in 5 studies, placebo was used as the comparison group; in 1 study, spironolactone was used as a comparison group; in 4 of the 9 reviewed studies modeling was used to evaluate cost-effectiveness; in 1 study clinical data were used; and four studies were designed as a clinical trial.

Modeling was used in 4 studies. The discrete event simulation model was used in 2 studies: Markov model in 1 study, and decision analysis model in another study.

In 5 studies, the perspective of health care system was used to evaluate cost-effectiveness. In 3 studies, social perspective and in 1 study perspective of third-party payer were used. In 6 studies, sensitivity analyses were conducted; and probabilistic sensitivity analyses (PSA) was one of the most important methods of sensitivity analyses in these studies.

The discount rate was 3% in 4 studies, 5% in 2, 4% in 1, and 3.5% in 1 study in England. In a study by Li et al., the discount rate was 3.5% for England and 3% for Spain.

In 5 out of 9 reviewed studies, the follow-up period was 1.3 years (16 months). In 1 study, the follow-up period was 7.08 years; follow-up period was 2 years in 1 study, and 10 years in another study; patients were examined for their remaining lifetime in 1 study.

In 2 studies, in which the discrete event simulation model was used, quality- adjusted life years were respectively 1.18, 1.22, and 1.33 (In a study by Li et al., quality-adjusted life years (QALY) was calculated for Britain and Spain). In studies using decision analysis model, the quality-adjusted life years was equal to 0.25. According to a study by Markov model, the quality-adjusted life years +was equal to 0.19.

Another 5 studies which used no modeling as their research method for calculating the quality-adjusted life years, could use 3 approaches based on the average: Framingham, Saskatchewan, and Worcester: the results are shown in [Figure 1](#F1){ref-type="fig"}.
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To calculate the total costs of treating cardiovascular patients with eplerenone, 3 studies used Euros, 2 studies used US\$, 1 study used Canadian dollars, and 1 study used Australian dollars, and the Swiss Franc was used in another study. Moreover, the total cost was not estimated in 1 study. Distribution of the annual average total cost of treating cardiovascular patients with eplerenone in different currencies is presented in [Figure 2](#F2){ref-type="fig"}.
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Although various methods were used to estimate the total cost in the articles, the considered factors for calculating the total cost and the exchange rate of the base year varied between the studies. Overall, the total cost was calculated to compare the costs of treatment with eplerenone in different countries. The costs were converted to US\$ based on the exchange rate on October 26, 2016.

As observed in [Figure 3](#F3){ref-type="fig"}, costs of treatment with eplerenone were approximately the highest in the United States and Switzerland and the lowest in Britain and Spain. Overall, the average of the total costs was equal to \$6694 annually.
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However, various methods have been used to estimate the cost per additional QALY. The exchange rate of the base year was different in the articles. Thus, to compare the costs, costs per additional QALY for treatment with eplerenone was calculated in different countries and converted to US\$ based on the exchange rate on October 26, 2016. The results are presented in [Figure 4](#F4){ref-type="fig"} for modeling studies and in Figure 5 for clinical trials and observational studies.
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There are some limitations in calculating a specific cost per additional QALY for treatment of patients based on the results of different studies in different situations ([Fig. 5](#F5){ref-type="fig"}). In the present study, the cost per additional QALY for the treatment of cardiovascular patients with eplerenone was estimated to be \$9478.
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Although the exchange rate of the base year was different, to compare the incremental cost-effectiveness ratios of eplerenone in different countries, costs were calculated and converted to US\$ according to the exchange rate on October 26, 2016. As shown in [Figure 6](#F6){ref-type="fig"}, the incremental cost-effectiveness ratio of treating cardiovascular patients with eplerenone was significantly higher in Australia compared to European countries and Canada.
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As observed in [Figure 7](#F7){ref-type="fig"}, the incremental cost-effectiveness ratio of treating cardiovascular patients with eplerenone was significantly higher in the United States compared to European countries. Results of quality assessment of the articles based on the Drummond checklist are demonstrated in [Table 2](#T2){ref-type="table"}. Average of the quality of articles was equal to 7.4 from 10.
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###### Information of the articles that studied the cost-effectiveness of eplerenone in the treatment of patients with cardiovascular diseases

  ------------------------------------------ ------------------- ------------------------------------------------------------------------------------------------------------------------------------------ ------------------------- -------------------- ---------------- --------------------------------- ------------------------- -------------------------------------------------------- ------------------------------- -------------------- --------------------------------- ------------------------------ ----------------------- -------------------------------------------------------------- --------------------------
  *Author, year of study*                    *Study site*        *Purpose of the study*                                                                                                                     *Participants (number)*   *Comparison group*   *Study design*   *Decision model*                  *Approach of the study*   *Sensitivity analysis*                                   *the discount rate (percent)*   *Follow-up period*   *QALY*                            *Total costs*                  *Costs Per each QAYL*   *Incremental cost-effectiveness ratio combined with quality*   *Drummond\'s Checklist*\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              *Score of ([@R10])*

  1\. Thanh et al. 2016 ([@R20])             Canada              Evaluation of the cost-effectiveness of eplerenone in patients with heart failure and mild systolic symptoms                               11055                     Standard treatment   modeling         Discrete event simulation model   Health                    Scenario, and probabilistic sensitivity analyses (PSA)   3                               7.08                 1.18                              Can\$40059                     Can\$5700               Can\$ 6100                                                     8

  2.McKenna et al. 2012 ([@R18])             England             Comparing the cost-effectiveness of eplerenone with spironolactone in patients with heart failure after myocardial infarction              3313                      Spironolactone       modeling         Decision analysis model           Health                    \-                                                       3.5                             2                    0.25                              \-                             £7893                   £4457                                                          7

  3\. Zhang et al. 2010 ([@R16])             America             Evaluation of the cost-effectiveness of eplerenone in patients with acute heart Failure after receiving ACE inhibitors and B-blockers      2113                      placebo              Observation      3                                 1.3                       \-                                                       Based on Framingham= 0.1148\    US\$14 563           Based on Framingham= US\$14926\   Based on Framingham= 25398\    5                       3                                                              1.3
                                                                                                                                                                                                                                                                                                                                                                                                 Saskatchewan = 0.0673\                               Saskatchewan = US\$25447\         Saskatchewan= 37664\                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                 Worcester= 0.1504                                    Worcester= US\$11393              Worcester= 21326                                                                                                      

  4\. De Pouvourville et al. 2008 ([@R17])   France              Evaluation of cost-effectiveness in patients with acute heart failure after myocardial infarction                                          3319                      Placebo              Trial            5                                 1.3                       Stochastic sensitivity analysis                          Based on Framingham= −0.0972\   £5783.6              Based on Framingham= £ 5721\      Based on Framingham= £ 9819\   7                       5                                                              1.3
                                                                                                                                                                                                                                                                                                                                                                                                 Saskatchewan = −0.0620                               Saskatchewan = £5721              Saskatchewan = £ 15382                                                                                                

  5\. Ademi et al. 2016 ([@R21])             Australia           Comparing the cost-effectiveness of eplerenone with current treatments in patients with chronic heart failure and NYHA^4^ class 2          1000                      Standard treatment   modeling         Markov Model                      Health                    Deterministic sensitivity analysis (DSA),\               5                               10                   0.19                              \$11,848,684                   \-                      \$37452                                                        8
                                                                                                                                                                                                                                                                                                                                        scenario, and PSA                                                                                                                                                                                                                                                     

  6.Weintraub et al. 2005 ([@R22])           America             Evaluation of the cost-effectiveness of eplerenone in myocardial infarction patients with heart failure and left ventricular dysfunction   3319                      Placebo              Trial            \-                                Social                    \-                                                       3                               1.3                  Based on Framingham= 0.0676\      \$13 494                       \-                      Based on Framingham= 29469\                                    9
                                                                                                                                                                                                                                                                                                                                                                                                                                                      Saskatchewan = 0.0429\                                                                   Saskatchewan= 43301\                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                      Worcester= 0.0907                                                                        Worcester= 23724                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  7\. Szucs et al. 2006([@R23])              Swiss               Evaluation of the cost-effectiveness of Eplerenone in myocardial infarction patients with heart failure and left ventricular dysfunction   3319                      Placebo              Trial            \-                                Third party payer         Univariate sensitivity analysis                          3                               1.3                  Based on Framingham= 0.1083\      Swiss Francs16969.78           Framingham= 15,219\     Framingham= 10145\                                             9
                                                                                                                                                                                                                                                                                                                                                                                                                                                      Saskatchewan = 0.0661\                                           Saskatchewan= 23,965\   Saskatchewan= 16178\                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                      Worcester= 0.1518                                                Worcester= 11,337       Worcester= 7693                                                

  8\. Lee et al. 2014 ([@R24])               England and Spain   Evaluation of the cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms                               1000                      Standard treatment   Modeling         Discrete event simulation model   Health                    PSA\                                                     England=3.5\                    Lifetime             = England\                        England =£18 559\              England = £2825\        England = £3520\                                               7
                                                                                                                                                                                                                                                                                                                                        DSA                                                      Spain=3                                              1.22\                             Spain = €23 353                Spain = €4431           Spain = €5532                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                      =Spain\                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                      1.33                                                                                                                                                    

  9\. Van Genugten et al. 2005 ([@R25])      Netherlands         Evaluation of the cost-effectiveness of eplerenone in myocardial infarction patients with heart failure and left ventricular dysfunction   3319                      Placebo              Trial            \-                                Health                    PSA                                                      4                               1.3                  Based on Framingham= 0.0661       £6035.6                        \-                      Based on Framingham =12147                                     7
  ------------------------------------------ ------------------- ------------------------------------------------------------------------------------------------------------------------------------------ ------------------------- -------------------- ---------------- --------------------------------- ------------------------- -------------------------------------------------------- ------------------------------- -------------------- --------------------------------- ------------------------------ ----------------------- -------------------------------------------------------------- --------------------------

^1^-Peeters A, Mamun AA, Willekens F, et al. A Cardiovascular Life History: A Life Course Analysis of the Original Framingham Heart Study cohort. Eur Heart J 2002; 23: 458-66.

^2^- Downey W, Beck P, McNutt M, et al. Health Databases in Saskatchewan. In: Ttrom BL, Editor. Pharmacoepidemiology. 3rd ed. Chichester: Wiley, 2000: 325-45.

^3^- Goldberg RJ, Yarzebski J, Lessard D, et al. A two-Decade (1975 to 1995) Long Experience in the Incidence, In-Hospital and Long-Term Case-Fatality Rates of Acute Myocardial Infarction: Acommunity-Wide Perspective. J Am Coll Cardiol 1999; 33 (6): 1533-9 New York Heart Association (NYHA).

###### Results of quality assessment of the articles on cost-effectiveness of treating cardiovascular patients by eplerenone based on the Drummond Checklist

  ------- ---------------------------------------------------------------------------------------------- ------------------- --------------------- ------------------- ----------------------------- ------------------- ----------------------- -------------------- ----------------- --------------------------
  *Row*   *Study* *Criteria*                                                                             Thanh et al. 2016   McKenna et al. 2012   Zhang et al. 2010   De Pouvourville et al. 2008   Ademi et al. 2016   Weintraub et al. 2005   Szucs et al.: 2006   Lee et al. 2014   Van Genugten et al: 2005

  1       Are good research questions asked?                                                             √                   √                     √                   √                             √                   √                       √                    √                 √

  2       Is comprehensive description of the competing alternatives offered?                            ×                   ×                     ×                   ×                             ×                   √                       ×                    ×                 ×

  3       Is there any evidence of effectiveness of the program?                                         √                   √                     √                   ×                             ×                   √                       √                    √                 √

  4       Are all important and relevant costs and consequences identified?                              √                   √                     √                   √                             √                   √                       √                    √                 √

  5       Are all important and relevant costs and consequences measured accurately?                     √                   √                     √                   √                             √                   √                       √                    √                 √

  6       Are all important and relevant costs and consequences valued accurately?                       √                   √                     √                   √                             √                   √                       √                    √                 √

  7       Are costs and outcomes adjusted for different times?                                           ×                   √                     ×                   √                             √                   √                       √                    ×                 ×

  8       Is an incremental analysis of costs and consequences of the competing alternatives done?       √                   √                     ×                   √                             √                   √                       √                    √                 √

  9       Is the effect of uncertainty (sensitivity analysis) to predict costs and outcomes studied?     √                   ×                     ×                   √                             √                   ×                       √                    √                 √

  10      Are all the associated issues with the users included in the analysis and presented results?   √                   √                     √                   √                             √                   √                       √                    √                 \
                                                                                                                                                                                                                                                                                        √
  ------- ---------------------------------------------------------------------------------------------- ------------------- --------------------- ------------------- ----------------------------- ------------------- ----------------------- -------------------- ----------------- --------------------------

Discussion {#s6}
==========

Eplerenone is one of the medications used for treating patients with heart failure after myocardial infarction, and it can also increase blood pressure. In the recent years, several studies have confirmed the effectiveness of this drug in reducing the mortality rate of cardiovascular patients and decreasing their hospital stay ([@R8],[@R10],[@R26]).

Few studies have been conducted on the cost-effectiveness of eplerenone in recent years, though robust evidence and information were not available. The current study, which systematically reviewed the results of 9 valid studies, it was found that the results of all the 9 studies approved the cost-effectiveness of this medication compared to the current treatments, the placebo, and similar drugs. The reviewed studies have been conducted between 2005 and 2016 in 8 countries (The United States, Britain, Australia, Switzerland, France, Spain, The Netherlands, and Canada). This indicates that eplerenone has just entered the consumer market recently, and like most other drugs, first it has been exploited on the market of high-income countries.

In 2002, eplerenone was approved by the Food and Drug Administration of America (FDA). Nowadays, this medication is mostly used in high-income countries such as the United States, Canada, and members of the EU (Japan and the European Union) ([@R27]).

In this context, these studies were mostly designed and conducted in high-income countries. Thus, these results are not fully applicable in low- and middle-income countries. Therefore, policymakers should benefit from the results of the localized studies in their decision-making.

The results of all the 9 studies approved the cost-effectiveness of this drug compared with the current treatments, the placebo, and similar drugs. One important point was that using eplerenone to treat cardiovascular patients was too costly compared to the comparison groups. However, eplerenone has a far greater impact on reducing the duration of hospitalization, decreasing the mortality rate of the cardiovascular patients, and ensuring efficacy and safety ([@R28]-[@R33]).

Eplerenone has been estimated to be more cost-effective than comparison groups in general. Therefore, considering the reports of cost-effectiveness of this medication cannot be the only factor to be considered in the decision- making process, and other factors and local conditions of each region should also be considered. One of the most important factors was economic and financial status, health care system of the region, and the country. Moreover, most of the data of these studies were extracted from a base study "EMPHASIS-HF\", which was a double-blind, multi-centered clinical trial. In the present study, 6632 patients from 671 centers from 37 countries were registered during 1999 and 2001 and the effectiveness of eplerenone and placebo was evaluated in treating patients with myocardial infarction in this study ([@R34]).

Due to the fact that this study had some limitations and shortcomings, using its data and relying on its methodology can distort the application and validity of the results of the other studies. The main objective of this study was to evaluate cost-effectiveness of eplerenone and this factor could have affected the results and conditions of the study.

The results revealed that total costs, cost per additional QALY, and incremental cost-effectiveness ratio were very different in various countries. For example, in a study by Li et al. (2014), which aimed at determining the cost-effectiveness of eplerenone in 2 groups of cardiovascular patients from Britain and Spain, it was found that eplerenone raised QALY up to 1.33 by an increase in direct costs up to 4284 EUR in the English patients and raised QALY up to 1.22 by an increase in direct costs up to 7358 EUR in the Spanish patients, moreover, they found that the cost indicators were higher in Spain than in the UK ([@R24]).

This can have various reasons, but it can mainly be due to the price of eplerenone in different countries. General and administrative costs in different countries also play an important role. In general, it seems that costs of using this medicine are higher in the United States and Australia compared to Europe.

What can be deduced from the overall results of the current study is that using eplerenone to treat cardiovascular patients is very costly although it leads to more efficient clinical outcomes. Thus, cost of using this medicine to treat heart failure is approximately \$3 per day and to treat hypertension is about \$6 per day ([@R27]).

These expenses may not seem so high at first glance, but treatment of cardiovascular patients usually requires a long period and the total cost would be very high. Also, these costs may be payable for the high-income countries such as the United States and Britain, but most patients in low- and middle-income countries will not be able to pay such prices. Therefore, if policymakers and health care planners decide to use this medicine in their own health care system, they should consider support mechanisms such as insurance.

The results of the quality assessment of reviewed articles indicated that articles had acceptable quality, and one of the main reasons for this could be the fact that the topic of the cost-effectiveness of eplerenone is so new, dominant, and important. This factor encourages the researchers to conduct more accurate articles and publish them in prestigious and high-quality journals. However, the researchers pay less attention to the application and generalization of the findings of the researches based on different users and consumers.

Eplerenone is a newcomer to pharmaceutical market and has not been used in many countries yet. This affects the way it should be used locally in those countries. The results of current research may fall useful while it come to application of related research results for policy making. One of the most important limitations of the present study was the heterogeneity of the results of studies that made the deductive reasoning and conducting quantitative analysis (meta-analysis) impossible. Thus, the explicit and precise estimation of the reported indicators was not possible, so this issue should be considered for using and generalizing the results.

Conclusion {#s8}
==========

Based on the results of the reviewed studies in this systematic review, it seems that eplerenone has acceptable cost-effectiveness compared to the current treatments, placebo, and similar medications. In this regard, these studies were designed and conducted in high-income countries and in different conditions with low- and middle-income countries; thus, the application of these results in low- and middle-income countries will be limited. Therefore, if policymakers and health care planners decide to use eplerenone in their own health care system, they should design and conduct specialized studies in their own local settings with the help of specialists and experts in health economics.
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